个人简介：

本科毕业于合肥工业大学（2007-2011），硕博毕业于美国华盛顿州立大学（2011-2017），师从“总统提名 20 位最有前途科学家”Susmita

Bose 教授。曾在美国维克森林再生医学研究所跟随再生医学之父Anthony Atala教授从事生物3D打印与再生医学研究。加入南京大学前曾任苏州诺普再生医学有限公司首席技术官，负责3D打印可吸收三类医疗器械的开发与转化，被授予创新领军人才称号。先后承担了江苏省自然科学基金、江苏省重点研发计划、国家重点研发计划等重要研究任务，并取得突出的研究成果，发表高影响力SCI文章与专著共23篇，引用超2000次，申请美国专利1项，中国专利17项。

目前主要研究方向为新型生物材料的开发、增材制造技术的改进、以及两者相结合在组织工程领域的应用。本课题组致力于医工结合，希望通过新技术的开发解决临床痛点，为广大患者带来福音。邮箱：dongxu.ke@nju.edu.cn

英文简介：

Dr. Ke Dongxu earned his bachelor's degree from Hefei University of Technology (2007‑2011) and completed his master’s and doctoral degrees at Washington State University (2011‑2017), under the mentorship of Professor Susmita Bose, who was nominated by the President as one of the 20 most promising scientists. After that, he conducted research on bioprinting and regenerative medicine at the Wake Forest Institute for Regenerative Medicine, working with the “father of regenerative medicine,” Professor Anthony Atala. Before joining Nanjing University, he served as Chief Technology Officer at Novaprint Therapeutics Co., Ltd., overseeing the development and translation of absorbable 3D‑printed Class‑III medical devices, and was honored as an innovative leading talent. He has led major research projects, including the Jiangsu Natural Science Foundation, Jiangsu Key R&D Program, and the National Key R&D Program, achieving outstanding results. Dr. Ke has published 23 high‑impact SCI papers and monographs, cited over 2,000 times, and holds one U.S. patent and 17 Chinese patents.

His current research focuses on the development of novel biomaterials, improvement of additive manufacturing technologies, and their combined applications in tissue engineering. The research group is dedicated to integrating medicine and engineering, aiming to address clinical challenges through new technologies and bring benefits to patients.